Modulight Bio
Tel Aviv, Israel· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $12M
Overview
Israeli optogenetics biotech leveraging light‑controlled GPCRs to treat refractory neurological disorders.
NeurologyPainEpilepsyMovement Disorders
Technology Platform
A gene‑therapy‑delivered bistable inhibitory GPCR opsin (eOPN3) combined with implantable light devices to achieve reversible, on‑demand silencing of overactive neurons.
Opportunities
First‑in‑human trials could unlock a new class of reversible, gene‑therapy‑based neuromodulation for refractory neurological disorders, tapping a multi‑billion‑dollar market.
Risk Factors
Technical challenges in safe gene‑vector delivery, long‑term device biocompatibility, and regulatory approval for combined gene‑therapy/optical products.
Competitive Landscape
Competitors such as NeuroPace, SetPoint Medical, and Magnetogenics focus on electrical or magnetic neuromodulation; Modulight differentiates with optogenetic precision and reversible GPCR‑mediated inhibition.